Robert Girard Montréal Partner/Associé

Robert Y. Girard

Partner
Jurisdiction Québec, 1983
Language(s) French, English
Office(s) Montréal
Contact
Business +1 514 397 4369
Email rgirard@fasken.com
Share

Overview

Robert's primary focus is in the areas of securities law, structured finance and financial products and investment funds. Robert acted as lead counsel on the establishment of several investment funds and as a director, in the management of such funds. As such, he has a in-dept knowledge of the legal and business pitfalls and challenges of these funds. In addition, Robert has extensive experience in the structuring, offering and sale of structured products, such as principal protected notes and hedge funds.

His work involves a wide variety of corporate finance transactions which includes initial public offerings, private placements, corporate finance transactions and acting on behalf of issuers, underwriters and promoters.

Robert's corporate finance experience has involved issuers in industries such as multi-assets structured conduits, portfolio managers, business trusts, biopharmaceutical companies and includes merger and acquisitions and divestitures.

Robert provides on-going advice to public and private corporate clients concerning continuous disclosure obligations, shareholders communications, corporate governance issues and general corporate matters.

Related Solutions

Industries

Practices

Client Work

  • Theratechnologies announces US$11 million financing, [Deal - Theratechnologies], On August 6, 2015, Theratechnologies Inc. closed a short-form prospectus offering of units which resulted in gross proceeds of $11,040,000. Euro Pacific Canada Inc. and Mackie Research Capital Corporation, the underwriters under the offering, exercised their over-allotment option prior to the clo...
  • Theratechnologies files preliminary prospectus for US IPO and further Canadian issuance, [Deal - Theratechnologies], On February 22, 2011, Theratechnologies Inc. (TSX: TH) announced that it had filed a preliminary short form base PREP prospectus in connection with a proposed cross-border offering of approximately 11 million common shares, with an over-allotment option of 15%. This offering will be Theratechnolo...
  • Pan-Canadian Investors Committee completes US$32 billion ABCP restructuring, [Deal - Confidential Client], On January 21, 2009, The Pan-Canadian Investors Committee for Third-Party Structured Asset-Backed Commercial Paper announced that the restructuring plan affecting $32 billion of thirdparty ABCP had been fully implemented. Pursuant to the terms of the plan, holders of affected ABCP will have their...
  • Theratechnologies and Merck affiliate close a collaboration and licensing agreement for Tesamorelin valued at US$215 million, [Deal - Theratechnologies], On December 16, 2008, Theratechnologies and EMD Serono Inc., an affiliate of Merck KGaA , closed their transaction related to a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV pat...
  • Theratechnologies closes US$29.7 million financing, [Deal - Theratechnologies], On February 13, 2008, Theratechnologies Inc. announced that it had successfully completed its recently announced public offering of 3,500,000 common shares at a price of $8.50 per share for gross proceeds of $29,750,000. The offering was made through a syndicate of underwriters led by BMO Capital...
  • Theratechnologies closes US$57.7 million bought deal financing, [Deal - Theratechnologies], On February 27, 2007, Theratechnologies Inc. announced that it had successfully completed its recently announced public offering of 6,875,000 common shares at a price of $8.40 per share for gross proceeds of $57,750,000. The offering was made through a syndicate of underwriters led by BMO Capital...
  • Private offering of notes of Whitehall Trust, Devonshire Trust, Foundation Trust and Apsley Trust, [Case - Confidential Client], Acted as trust counsel in the private offering of notes of Whitehall Trust, Devonshire Trust, Foundation Trust and Apsley Trust, single purpose trusts established for the purpose of acquiring structured financial assets, including corporate, ABS and CMBS credit derivatives and synthetic credit ex...
  • Two Schedule B banks offer a principal protected notes program, [Case - Confidential Client], Represents, on an ongoing basis, two Schedule B banks in their offering of principal protected notes program.
Deal Advised Theratechnologies Theratechnologies announces US$11 million financing On August 6, 2015, Theratechnologies Inc. closed a short-form prospectus offering of units which resulted in gross proceeds of $11,040,000. Euro Pacific Canada Inc. and Mackie Research Capital Corporation, the underwriters under the offering, exercised their over-allotment option prior to the clo... Read more
Deal Advised Theratechnologies Theratechnologies files preliminary prospectus for US IPO and further Canadian issuance On February 22, 2011, Theratechnologies Inc. (TSX: TH) announced that it had filed a preliminary short form base PREP prospectus in connection with a proposed cross-border offering of approximately 11 million common shares, with an over-allotment option of 15%. This offering will be Theratechnolo... Read more
Deal Advised Confidential Client Pan-Canadian Investors Committee completes US$32 billion ABCP restructuring On January 21, 2009, The Pan-Canadian Investors Committee for Third-Party Structured Asset-Backed Commercial Paper announced that the restructuring plan affecting $32 billion of thirdparty ABCP had been fully implemented. Pursuant to the terms of the plan, holders of affected ABCP will have their... Read more
Deal Advised Theratechnologies Theratechnologies and Merck affiliate close a collaboration and licensing agreement for Tesamorelin valued at US$215 million On December 16, 2008, Theratechnologies and EMD Serono Inc., an affiliate of Merck KGaA , closed their transaction related to a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV pat... Read more
Deal Advised Theratechnologies Theratechnologies closes US$29.7 million financing On February 13, 2008, Theratechnologies Inc. announced that it had successfully completed its recently announced public offering of 3,500,000 common shares at a price of $8.50 per share for gross proceeds of $29,750,000. The offering was made through a syndicate of underwriters led by BMO Capital... Read more
Deal Advised Theratechnologies Theratechnologies closes US$57.7 million bought deal financing On February 27, 2007, Theratechnologies Inc. announced that it had successfully completed its recently announced public offering of 6,875,000 common shares at a price of $8.40 per share for gross proceeds of $57,750,000. The offering was made through a syndicate of underwriters led by BMO Capital... Read more
Case Represented Confidential Client Private offering of notes of Whitehall Trust, Devonshire Trust, Foundation Trust and Apsley Trust Acted as trust counsel in the private offering of notes of Whitehall Trust, Devonshire Trust, Foundation Trust and Apsley Trust, single purpose trusts established for the purpose of acquiring structured financial assets, including corporate, ABS and CMBS credit derivatives and synthetic credit ex... Read more
Case Represented Confidential Client Two Schedule B banks offer a principal protected notes program Represents, on an ongoing basis, two Schedule B banks in their offering of principal protected notes program. Read more

Career & Education

Education

  • LL.L. University of Ottawa
  • B. Soc. Sc. University of Ottawa

Memberships & Affiliations

  • Canadian Bar Association
  • Québec Bar
  • Director and Officer of the Manager of one private business trust
  • Director and officer of Global Digit Management Inc., a corporation acting as manager and trustee of Global Diversified Investment Grade Income Trust I (TSX : DGT.UN)
  • Member, Board of Directors, Pointe-à-Callière Museum of Archaeology and History Montreal Foundation
  • Member, Bar of Montréal

News

  • Mission accomplished: Three Fasken Martineau partners from the Montréal office participated in the 8th annual Grand défi Pierre Lavoie, 6/20/2016
News Release Mission accomplished: Three Fasken Martineau partners from the Montréal office participated in the 8th annual Grand défi Pierre Lavoie Montréal (Canada) – Fasken Martineau, a leading international business law and litigation firm, is proud to announce that partners Éric Bédard, Robert Girard and Robert Paré from the  Montréal office participated in the 8th annual Grand défi Pierre Lavoie (GDPL) event this past weekend. Travell... Read more

    Subscribe

    Receive email updates from our team

    Subscribe